EMC announced Documentum Submission, Store and View, for simplified storage, search, and retrieval of submission documentation and all associated correspondence...
As part of the EMC Documentum for Life Sciences Solution Suite, EMC announced Documentum Submission, Store and View (SSV), for simplified storage, search and retrieval of submission documentation and all associated correspondence, which adheres to security and compliance regulations.
Documentum SSV links regulatory correspondence and communications to submission files, enabling a 360-degree view of regulatory activity. It also automatically stores electronic common technical documents (eCTD), non-eCTD electronic submissions (NeeS) and paper submissions into a scalable Documentum repository that delivers advanced security, audit trail, metadata and indexing capabilities.
In a conversation with Applied Clinical Trials, Lori McKellar, Director, Market Development, and Steve Scribner, Principal Consultant, both with Life Sciences at EMC, told us that the solution can be hosted or on-premise and offers leveled access controls for the sponsor and their affiliated regulatory representatives. Further, Scribner explained the need for a full-view of the regulatory communications as sponsors simultaneously file multiple submissions to different global regulatory authorities, primarily through local affiliates, a contracted service. “The sponsors and CROs need this local expertise. Submissions aren’t the same for each country and the affiliate carries on that level of detail,” said Scribner. The danger is that the agency will communicate to an affiliate, and that information will be misunderstood or not make it in a timely fashion to the sponsor.
More specifically, EMC Documentum SSV enables:
Read the full release on their blog here.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.